Alphabet Inc. reported the indirect acquisition of 1.5 million shares of Prime Medicine, Inc.’s common stock through its investment arm GV, according to a Form 4 filed with the U.S. Securities and Exchange Commission.
The shares were purchased at a price of $3.30 each in a public offering that closed on August 1, resulting in a total transaction value of approximately $4.95 million.
The acquisition was made by GV 2021, L.P., a fund controlled through a chain of affiliated entities including GV 2021 GP, L.P., GV 2021 GP, L.L.C., Alphabet Holdings LLC, XXVI Holdings Inc., and ultimately Alphabet Inc.
Following the transaction, GV 2021, L.P. beneficially owns 3,262,440 shares of Prime Medicine common stock. The filing states that Alphabet and its affiliates may be deemed to have indirect beneficial ownership of the shares but disclaim such ownership except to the extent of any pecuniary interest.
The filing was signed by representatives of GV 2021, L.P., its general partners, and Alphabet Inc. on August 5.
